Eli Lilly Reports (CHALLENGE-MIG) Trial Results of Emgality (galcanezumab-gnlm) for the Prevention of Episodic Migraine
Shots:
- The (CHALLENGE-MIG) trial evaluating the efficacy and safety of Emgality (galcanezumab-gnlm) vs Nurtec ODT in 580 patients with episodic migraine
- The therapy showed robust efficacy for patients consistent with prior studies & failed to achieve statistical superiority over Nurtec ODT on the 1EPs based on the percentage of patients who achieved a ≥50% reduction in monthly migraine headache days, response rates were similar
- Emgality performed numerically better than Nurtec ODT on key 2EPs of 3mos. trial while the safety profiles were consistent with those previously reported for both treatments with no new safety findings. The full results will be presented in 2023
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Eli Lilly Reports the Availability of Emgality (galcanezumab) to Prevent Migraine in Canada
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
